Draig Therapeutics

Draig Therapeutics is a biotechnology firm focused on developing next-generation treatments for neuropsychiatric disorders. The company's strategy centers on creating highly targeted neuromodulators designed to fine-tune neurotransmission by modulating glutamate and GABA A receptors. This approach aims to restore the balance between excitatory and inhibitory signaling in the brain, a disruption of which is linked to various neuropsychiatric conditions.

The company's lead candidate, DT-101, is an AMPA receptor positive allosteric modulator (PAM) being developed as a treatment for Major Depressive Disorder (MDD). This asset is scheduled to enter Phase 2 clinical trials in 2025. The target market for MDD is substantial, with over 30 million individuals diagnosed and treated in the US and Europe alone.

Draig Therapeutics operates as a clinical-stage drug development company. Its business model involves advancing a pipeline of proprietary compounds through clinical trials to demonstrate safety and efficacy. The primary path to revenue generation for a company at this stage is typically through strategic partnerships, licensing agreements with larger pharmaceutical companies, or eventual acquisition upon successful clinical data.

The operational and strategic drug development is guided by a leadership team with extensive experience in the biotech industry, particularly in neurology and clinical development.

Keywords: neuropsychiatric disorders, neuromodulators, allosteric modulators, MDD, AMPA receptor, clinical trials, drug development, biotechnology, glutamate, GABA A